Pseudomonic acid—a new antibiotic for skin infections

Reilly, Graham D.; Spencer, R C

doi:10.1093/jac/13.3.295

Cited by 12 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mupirocin (first known as pseudomonic acid A) is produced naturally by Pseudomonas fluorescens (63). First used clinically in the 1980s, mupirocin is administered exclusively as a topical agent, as either a cream or an ointment (64)(65)(66)(67)(68)(69)(70). However, when it is administered systemically, mupirocin is rapidly degraded to an inactive metabolite, monic acid.…”

Section: Currently Used Topical Antibacterial Agents Mupirocinmentioning

confidence: 99%

Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns

2017

View full text Add to dashboard Cite

Bacterial skin infections represent some of the most common infectious diseases globally. Prevention and treatment of skin infections can involve application of a topical antimicrobial, which may be an antibiotic (such as mupirocin or fusidic acid) or an antiseptic (such as chlorhexidine or alcohol). However, there is limited evidence to support the widespread prophylactic or therapeutic use of topical agents. Challenges involved in the use of topical antimicrobials include increasing rates of bacterial resistance, local hypersensitivity reactions (particularly to older agents, such as bacitracin), and concerns about the indiscriminate use of antiseptics potentially coselecting for antibiotic resistance. We review the evidence for the major clinical uses of topical antibiotics and antiseptics. In addition, we review the mechanisms of action of common topical agents and define the clinical and molecular epidemiology of antimicrobial resistance in these agents. Moreover, we review the potential use of newer and emerging agents, such as retapamulin and ebselen, and discuss the role of antiseptic agents in preventing bacterial skin infections. A comprehensive understanding of the clinical efficacy and drivers of resistance to topical agents will inform the optimal use of these agents to preserve their activity in the future.

show abstract

Section: Currently Used Topical Antibacterial Agents Mupirocinmentioning

confidence: 99%

Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns

2017

View full text Add to dashboard Cite

show abstract

“…Mupirocin has undergone many clinical trials in the treatment of a wide range of skin infections (180)(181)(182)(183) and has successfully eliminated nasal carriage of methicillinresistant St. aureuc (184). The conclusion, so far, is that mupirocin is well tolerated and highly effective.…”

Section: Pseudomonic Acidmentioning

confidence: 99%